CN1929837A - 作为神经保护剂和/或神经再生剂的非免疫抑制的亲免素配体 - Google Patents

作为神经保护剂和/或神经再生剂的非免疫抑制的亲免素配体 Download PDF

Info

Publication number
CN1929837A
CN1929837A CNA2005800070342A CN200580007034A CN1929837A CN 1929837 A CN1929837 A CN 1929837A CN A2005800070342 A CNA2005800070342 A CN A2005800070342A CN 200580007034 A CN200580007034 A CN 200580007034A CN 1929837 A CN1929837 A CN 1929837A
Authority
CN
China
Prior art keywords
disease
compound
meridamycin
formula
dementia
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CNA2005800070342A
Other languages
English (en)
Chinese (zh)
Inventor
E·I·格拉齐阿尼
K·庞
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Wyeth LLC
Original Assignee
Wyeth LLC
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Wyeth LLC filed Critical Wyeth LLC
Publication of CN1929837A publication Critical patent/CN1929837A/zh
Pending legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4738—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4745—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems condensed with ring systems having nitrogen as a ring hetero atom, e.g. phenantrolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/02—Muscle relaxants, e.g. for tetanus or cramps
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Neurology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Epidemiology (AREA)
  • Pain & Pain Management (AREA)
  • Psychology (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Cardiology (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Saccharide Compounds (AREA)
CNA2005800070342A 2004-03-02 2005-02-25 作为神经保护剂和/或神经再生剂的非免疫抑制的亲免素配体 Pending CN1929837A (zh)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US54943004P 2004-03-02 2004-03-02
US60/549,430 2004-03-02

Publications (1)

Publication Number Publication Date
CN1929837A true CN1929837A (zh) 2007-03-14

Family

ID=34919492

Family Applications (1)

Application Number Title Priority Date Filing Date
CNA2005800070342A Pending CN1929837A (zh) 2004-03-02 2005-02-25 作为神经保护剂和/或神经再生剂的非免疫抑制的亲免素配体

Country Status (8)

Country Link
US (1) US20050197356A1 (enExample)
EP (1) EP1720548A1 (enExample)
JP (1) JP2007526312A (enExample)
CN (1) CN1929837A (enExample)
AU (1) AU2005219389A1 (enExample)
BR (1) BRPI0508084A (enExample)
CA (1) CA2556771A1 (enExample)
WO (1) WO2005084673A1 (enExample)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BRPI0508224A (pt) * 2004-03-02 2007-07-17 Wyeth Corp composto ou um sal farmaceuticamente aceitável do mesmo, cepa de actinomiceto, isolado de uma cepa, métodos para a produção de um macrolìdeo e de um composto, produto, composição, métodos de tratamento de um mamìfero e de um distúrbio neurológico, e, uso de um composto
JP2008501342A (ja) * 2004-06-03 2008-01-24 ワイス 複合ポリケチドを生成するための生合成遺伝子クラスター
TW200800959A (en) * 2005-06-10 2008-01-01 Wyeth Corp Piperazine-piperidine antagonists and agonists of the 5-HT1a receptor
JP2009529049A (ja) * 2006-03-07 2009-08-13 ワイス 神経障害の治療のためのメリダマイシン類似体
TW200808740A (en) * 2006-06-09 2008-02-16 Wyeth Corp Succinate salts of 6-methoxy-8-[4-(1-(5-fluoro)-quinolin-8-yl-piperidin-4-yl)-piperazin-1-yl]-quinoline and crystalline forms thereof
TW200808741A (en) * 2006-06-09 2008-02-16 Wyeth Corp 6-methoxy-8-[4-(1-(5-fluoro)-quinolin-8-yl-piperidin-4-yl)-piperazin-1-yl]-quinoline hydrochloric acid salts
TW200811144A (en) * 2006-06-09 2008-03-01 Wyeth Corp Crystalline forms of 6-methoxy-8-[4-(1-(5-fluoro)-quinolin-8-yl-piperidin-4-yl)-piperazin-1-yl]-quinoline
TW200831096A (en) * 2006-11-28 2008-08-01 Wyeth Corp Metabolites of 5-Fluoro-8-{4-[4-(6-methoxyquinolin-8-yl)piperazin-1-yl]piperidin-1-yl} quinoline and methods of preparation and uses thereof
TW200901974A (en) 2007-01-16 2009-01-16 Wyeth Corp Compounds, compositions, and methods of making and using them
CA2676613A1 (en) * 2007-01-29 2008-08-07 Wyeth Immunophilin ligands and methods for modulating immunophilin and calcium channel activity
EP3139174B1 (en) 2009-09-24 2018-11-07 Etienne Baulieu Fkbp52-tau interaction as a novel therapeutical target for treating the neurological disorders involving tau dysfunction

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9302016D0 (en) * 1993-02-02 1993-03-17 Sandoz Ltd Compounds
UA41884C2 (uk) * 1993-11-05 2001-10-15 Амерікан Хоум Продактс Корпорейшн Спосіб відокремлення рапаміцину від кислотних, основних та неполярних нейтральних домішок, присутніх в концентраті екстрактів ферментаційного бульйону або маточних розчинів
US5696135A (en) * 1995-06-07 1997-12-09 Gpi Nil Holdings, Inc. Inhibitors of rotamase enzyme activity effective at stimulating neuronal growth
US6242468B1 (en) * 1997-02-27 2001-06-05 Jia-He Li Carbamate and urea compositions and neurotrophic uses
US7041283B1 (en) * 2001-02-16 2006-05-09 University Of Pittsburgh-Of The Commonwealth System Of Higher Education Methods of using immunophilin binding drugs to improve integration and survival of neuronal cell transplants

Also Published As

Publication number Publication date
US20050197356A1 (en) 2005-09-08
BRPI0508084A (pt) 2007-07-17
WO2005084673A1 (en) 2005-09-15
JP2007526312A (ja) 2007-09-13
AU2005219389A1 (en) 2005-09-15
CA2556771A1 (en) 2005-09-15
EP1720548A1 (en) 2006-11-15

Similar Documents

Publication Publication Date Title
US20110144176A1 (en) Macrolides and methods for producing same
Jayasuriya et al. Isolation and structure elucidation of thiazomycin
MXPA97003484A (en) Macrocyclic lactone compounds and their product procedure
CN1867664A (zh) 使用新的链霉菌菌种生产他克莫司(fk－506)
US20050197356A1 (en) Non-immunosuppressive immunophilin ligands as neuroprotective and/or neuroregenerative agents
US20040229323A1 (en) Process for producing anticancer agent LL-D45042
WO1994018207A1 (en) Rapamycin-like macrolide and a new strain of streptomyces which produces it
CN1165547C (zh) 与阿卡加定相关的新型羊毛硫抗生素及其制备方法和用途
CN1082052C (zh) 制备环状缩肽化合物的方法和新的环状缩肽
CN1849313A (zh) 抗生素化合物
EP2441767B1 (en) Salinosporamides and methods for use thereof
KR100226305B1 (ko) 폴리히드록시 시클로펜탄유도체, 그의 제조방법 및 그의 치료적용도
CN1422252A (zh) 受体拮抗剂趋化因子
CN1152881C (zh) 从海洋放线菌中得到的新吲哚并咔唑生物碱及其组合物和用途
JP3521110B2 (ja) 環状ペプチド化合物及びその製造方法
JPWO2005061461A1 (ja) ヒートショックプロテイン９０（ｈｓｐ９０）ファミリー蛋白質阻害剤
CN1279906C (zh) 硫藤黄菌素二氧化物及其衍生物在制备用于治疗cns疾病的药物中的用途及其制备方法
MXPA06009994A (en) Macrolides and methods for producing same
CN1875012A (zh) 2－苯基苯并呋喃衍生物、其产生方法和它们的用途
MXPA06009926A (en) Non-immunosuppressive immunophilin ligands as neuroprotective and/or neuroregenerative agents
JP2006528664A (ja) ポリエンポリケチド、その調製方法及び医薬品としてのその使用
CN1217929C (zh) 阿考霉素,其生产方法及其作为药物的用途
WO2010019659A1 (en) Pyrrolo[4,3,2-de]quinolin-8-amine compounds and methods of their preparation and use
DK2441767T3 (en) Salinosporamider and methods of use thereof
WO2008024285A2 (en) Antibiotic compound

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
C02 Deemed withdrawal of patent application after publication (patent law 2001)
WD01 Invention patent application deemed withdrawn after publication